AstraZene- AZD3632 Mono or in Comb with Anticancer Agents in subjects with w/ KMT2Ar, NPM1m, w/ HOX - Clinical Trial
What is the Purpose of this Study?
This study has three parts:
- Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work.
- Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups:
- One group gets AZD3632 alone.
-The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions.
- After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.
Adults with acute leukemia or myelodysplastic syndromes (MDS)
Who Can Participate in the Study?
Adults with certain blood cancers; like AML, ALL, MPAL, AUL, or MDS—can join this study. Some parts of the study are for people whose cancer has come back, which means there are more than 5% cancer cells in their bone marrow again.
What is Involved?
This study is being done to see if a new medicine called AZD3632 is safe and works well for people with certain blood cancers called acute leukemia or MDS.
Study Details
